What’s new

• Standalone revenue surged 475% to ₹177.23 crore; net profit rose to ₹3.71 crore.
• First consolidated results filed, showing ₹182.85 crore in revenue from new subsidiary Gabriel Ingrevia.
• Gabriel Ingrevia acquired 95% of Drug Centre's business in March 2026, after the reporting period.

Why it matters

The numbers confirm a fundamental reset for a nano-cap pet-strap maker. The consolidated filing, enabled by a new subsidiary, reveals a pharma distribution business is now the dominant revenue driver.

What we’re watching

• First full-year operational performance of the Drug Centre business in FY27.
• How the thinning profit margins evolve as the new business scales.
• Any further capital raises to fund the expanded operations.

The full read

Gabriel Pet Straps posted standalone revenue of ₹177.23 crore for FY26. That's up nearly 5x from ₹30.84 crore. Net profit grew to ₹3.71 crore from ₹1.56 crore, but the margin clearly thinned. The real shift is in the first-ever consolidated numbers: ₹182.85 crore in revenue. That comes from Gabriel Ingrevia, a subsidiary set up in April 2025. Ingrevia bought 95% of Drug Centre's business in March. The deal closed after the year ended. Its full operational impact is yet to be felt. For a ₹98 crore market-cap firm, this is a fundamental reset.

Primary source: BSE · NSE